These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 6132036)

  • 1. Endralazine, a new peripheral vasodilator: absence of effect of acetylator status on antihypertensive effect.
    Holmes DG; Bogers WA; Wideroe TE; Huunan-Seppala A; Wideroe B
    Lancet; 1983 Mar; 1(8326 Pt 1):670-1. PubMed ID: 6132036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A dose-finding study of the combination of pindolol, clopamide and endralazine in the treatment of moderate-to-severe hypertension.
    Seedat YK; Rawat R
    S Afr Med J; 1984 Nov; 66(18):682-4. PubMed ID: 6387966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endralazine, a new peripheral vasodilator. Evaluation of safety and efficacy over a 3 year period.
    Bogers WA; Meems L
    Eur J Clin Pharmacol; 1983; 24(3):301-5. PubMed ID: 6861845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical evaluation of endralazine (BO22708), a new vasodilator, in essential hypertension.
    Elliott HL; McLean K; Sumner DJ; Donnelly RJ; Reid JL
    Clin Exp Hypertens A; 1982; 4(8):1409-18. PubMed ID: 6749347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of once daily endralazine in hypertension.
    Wu R; Spence JD; Carruthers SG
    Eur J Clin Pharmacol; 1986; 30(5):553-7. PubMed ID: 3758143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacokinetics of endralazine in essential hypertensives and in normotensive subjects.
    Meredith PA; Elliott HL; McSharry DR; Kelman AW; Reid JL
    Br J Clin Pharmacol; 1983 Jul; 16(1):27-32. PubMed ID: 6882620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of acetylator phenotype on the pharmacokinetics of a new vasodilator antihypertensive, endralazine.
    Reece PA; Cozamanis I; Zacest R
    Eur J Clin Pharmacol; 1982; 23(6):523-7. PubMed ID: 7160421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endralazine, a new peripheral vasodilator--a randomized cross-over trial against dihydralazine.
    Kirch W; Axthelm T
    J Cardiovasc Pharmacol; 1982; 4(4):562-6. PubMed ID: 6181329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endralazine and acetylator phenotype.
    Meems L; Bogers WA
    Lancet; 1983 May; 1(8335):1220-1. PubMed ID: 6134015
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of food intake on plasma levels and antihypertensive response during maintenance therapy with endralazine.
    Kindler J; Rüegg PC; Neuray M; Pacha W
    Eur J Clin Pharmacol; 1987; 32(4):367-72. PubMed ID: 3609114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endralazine - a new hydralazine-like antihypertensive with high systemic bioavailability.
    Reece PA; Cozamanis I; Zacest R
    Eur J Clin Pharmacol; 1983; 25(4):553-6. PubMed ID: 6653651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of once daily endralazine with placebo in the treatment of hypertension uncontrolled by a beta-blocker and diuretic.
    McGourty JC; Silas JH; Pidgeon J
    Eur J Clin Pharmacol; 1985; 29(4):401-3. PubMed ID: 2868900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative study of endralazine and hydralazine for the treatment of hypertension uncontrolled by a beta-blocker and diuretic.
    Chazan BI; Duff DA; McCallum A; Whaley K
    Curr Med Res Opin; 1986; 10(3):150-8. PubMed ID: 2873966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the vasodilator endralazine given with the antihypertensive agent guanfacine on heart rate and blood pressure of spontaneously hypertensive rats and normotensive dogs.
    Salzmann R; Gerber W; Pally C; Scholtysik G
    J Pharm Pharmacol; 1983 May; 35(5):293-8. PubMed ID: 6134797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue distribution of endralazine and its clinical effect in refractory hypertension.
    Kindler J; Moedder G; Sieberth HG
    Contrib Nephrol; 1985; 49():193-200. PubMed ID: 3830566
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical pharmacological studies with the vasodilator endralazine in normotensive subjects and essential hypertensives.
    Elliott HL; Meredith PA; Howden CW; Lawrie CB; Reid JL
    Int J Clin Pharmacol Res; 1984; 4(1):61-9. PubMed ID: 6469433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic and pharmacokinetic studies with the vasodilator endralazine.
    Elliott HL; Meredith PA; Reid JL
    J Hypertens Suppl; 1984 Dec; 2(3):S551-4. PubMed ID: 6599716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of intravenous endralazine in essential hypertension.
    Hoffmann JJ; Thien T; van T'Laar A
    Br J Clin Pharmacol; 1983 Jul; 16(1):39-44. PubMed ID: 6349669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different phenotypes of the NAT2 gene influences hydralazine antihypertensive response in patients with resistant hypertension.
    Spinasse LB; Santos AR; Suffys PN; Muxfeldt ES; Salles GF
    Pharmacogenomics; 2014 Feb; 15(2):169-78. PubMed ID: 24444407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should the acetylator phenotype be determined when prescribing hydralazine for hypertension?
    Ramsay LE; Silas JH; Ollerenshaw JD; Tucker GT; Phillips FC; Freestone S
    Eur J Clin Pharmacol; 1984; 26(1):39-42. PubMed ID: 6714290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.